Novel Experimental Mouse Model to Study the Pathogenesis and Therapy of Actinobacillus pleuropneumoniae Infection

Duc-Thang Bui,Yi-San Lee,Tien-Fen Kuo,Zeng-Weng Chen,Wen-Chin Yang
DOI: https://doi.org/10.3390/pathogens13050412
IF: 3.7
2024-05-16
Pathogens
Abstract:Actinobacillus pleuropneumoniae (APP) is a major cause of lung infections in pigs. An experimental mouse has the edge over pigs pertaining to the ease of experimental operation, disease study and therapy, abundance of genetic resources, and cost. However, it is a challenge to introduce APP into a mouse lung due to the small respiratory tract of mice and bacterial host tropism. In this study, an effective airborne transmission of APP serovar 1 (APP1) was developed in mice for lung infection. Consequently, APP1 infected BALB/c mice and caused 60% death within three days of infection at the indicated condition. APP1 seemed to enter the lung and, in turn, spread to other organs of the mice over the first 5 days after infection. Accordingly, APP1 damaged the lung as evidenced by its morphological and histological examinations. Furthermore, ampicillin fully protected mice against APP1 as shown by their survival, clinical symptoms, body weight loss, APP1 count, and lung damages. Finally, the virulence of two extra APP strains, APP2 and APP5, in the model was compared based on the survival rate of mice. Collectively, this study successfully established a fast and reliable mouse model of APP which can benefit APP research and therapy. Such a model is a potentially useful model for airway bacterial infections.
microbiology
What problem does this paper attempt to address?
The problem this paper attempts to address is the establishment of a novel mouse experimental model for studying and treating Actinobacillus pleuropneumoniae (APP) infection. Specifically, the main objectives of the paper include: 1. **Developing an effective aerosol transmission method**: Introducing APP into the lungs of mice via aerosol, overcoming the challenges of traditional methods (such as intranasal instillation and intraperitoneal injection) related to the narrow respiratory tract of mice and the host specificity of bacteria. 2. **Evaluating the pathological changes after APP infection in mice**: Detailed description of the pathological changes caused by APP1 (APP serotype 1) infection in mice, including mortality rate, clinical symptoms, weight changes, bacterial load, and lung damage. 3. **Assessing the effectiveness of antibiotic treatment**: Testing the therapeutic effect of Ampicillin on APP1-infected mice, including improvements in survival rate, clinical symptoms, weight changes, bacterial load, and lung damage. 4. **Comparing the virulence of different APP serotypes**: Comparing the lethality of APP2 (low virulence) and APP5 (high virulence) in mice using the same model to verify the applicability and reliability of the model. In summary, this study aims to establish a rapid and reliable mouse model of APP infection to better understand the mechanisms of disease occurrence and treatment methods, and to provide a reference for the study of other respiratory bacterial infections.